New Insights Into Pathophysiology of β-Thalassemia
- PMID: 35492364
- PMCID: PMC9041707
- DOI: 10.3389/fmed.2022.880752
New Insights Into Pathophysiology of β-Thalassemia
Abstract
β-thalassemia is a disease caused by genetic mutations including a nucleotide change, small insertions or deletions in the β-globin gene, or in rare cases, gross deletions into the β-globin gene. These mutations affect globin-chain subunits within the hemoglobin tetramer what induces an imbalance in the α/β-globin chain ratio, with an excess of free α-globin chains that triggers the most important pathogenic events of the disease: ineffective erythropoiesis, chronic anemia/chronic hypoxia, compensatory hemopoietic expansion and iron overload. Based on advances in our knowledge of the pathophysiology of β-thalassemia, in recent years, emerging therapies and clinical trials are being conducted and are classified into three major categories based on the different approach features of the underlying pathophysiology: correction of the α/β-globin disregulation; improving iron overload and reverse ineffective erythropoiesis. However, pathways such as the dysregulation of transcriptional factors, activation of the inflammasome, or approach to mechanisms of bone mineral loss, remain unexplored for future therapeutic targets. In this review, we update the main pathophysiological pathways involved in β-thalassemia, focusing on the development of new therapies directed at new therapeutic targets.
Keywords: GATA1; anemia; inflammasome; thalassemia; β-globin.
Copyright © 2022 Sanchez-Villalobos, Blanquer, Moraleda, Salido and Perez-Oliva.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Emerging Therapies in β-Thalassemia.Hematol Oncol Clin North Am. 2023 Apr;37(2):449-462. doi: 10.1016/j.hoc.2022.12.010. Hematol Oncol Clin North Am. 2023. PMID: 36907614 Review.
-
Novel Therapeutic Advances in β-Thalassemia.Biology (Basel). 2021 Jun 18;10(6):546. doi: 10.3390/biology10060546. Biology (Basel). 2021. PMID: 34207028 Free PMC article. Review.
-
Recent trends in treatment of thalassemia.Blood Cells Mol Dis. 2019 May;76:53-58. doi: 10.1016/j.bcmd.2019.01.006. Epub 2019 Feb 4. Blood Cells Mol Dis. 2019. PMID: 30792169 Review.
-
Beta-thalassemia.Genet Med. 2010 Feb;12(2):61-76. doi: 10.1097/GIM.0b013e3181cd68ed. Genet Med. 2010. PMID: 20098328 Review.
-
Emerging therapies in β-thalassemia: toward a new era in management.Expert Opin Emerg Drugs. 2020 Jun;25(2):113-122. doi: 10.1080/14728214.2020.1752180. Epub 2020 Apr 15. Expert Opin Emerg Drugs. 2020. PMID: 32249632 Review.
Cited by
-
Unraveling Impact of Hemoglobin F and A2 Levels: Correlation With Disease Severity and Treatment Response in Transfusion-Dependent Beta-Thalassemia.Cureus. 2024 Jan 10;16(1):e52002. doi: 10.7759/cureus.52002. eCollection 2024 Jan. Cureus. 2024. PMID: 38344549 Free PMC article.
-
Therapeutic Relevance of Inducing Autophagy in β-Thalassemia.Cells. 2024 May 25;13(11):918. doi: 10.3390/cells13110918. Cells. 2024. PMID: 38891049 Free PMC article. Review.
-
Decrease in α-Globin and Increase in the Autophagy-Activating Kinase ULK1 mRNA in Erythroid Precursors from β-Thalassemia Patients Treated with Sirolimus.Int J Mol Sci. 2023 Oct 10;24(20):15049. doi: 10.3390/ijms242015049. Int J Mol Sci. 2023. PMID: 37894732 Free PMC article.
-
Serum visfatin level in β-thalassemia and its correlation with disease severity.J Med Life. 2024 Mar;17(3):314-317. doi: 10.25122/jml-2023-0354. J Med Life. 2024. PMID: 39044939 Free PMC article.
-
Precise correction of a spectrum of β-thalassemia mutations in coding and non-coding regions by base editors.Mol Ther Nucleic Acids. 2024 May 3;35(2):102205. doi: 10.1016/j.omtn.2024.102205. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38817682 Free PMC article.
References
-
- Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. (eds.). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia: Thalassaemia International Federation; (2014). - PubMed
Publication types
LinkOut - more resources
Full Text Sources